Thor Medical ASA TRMED
OSL · Norway · Commercial Services
NOK 4.46-0.01 (-0.34%)
Market closed· · NOK · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · NOK · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Thor Medical ASA (STU:8NN) outlines its path to profitability with a robust order backlog and strategic funding, despite current financial losses.
OSLO, Norway and HOUSTON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Thor Medical ASA, a leading emerging supplier of alpha-emitters for next-generation precision cancer treatment, and RadioMedix, Inc., a U.S. based clinical-stage biotechnology company focused on innovative targeted radiopharmaceuticals for diagnosis, monitoring and cancer therapy, have entered into a five-year frame agreement for the supply of thorium-228 (Th-228). The supply of Th-228 will start in 2026, with volumes scaling with incre
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.